Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme. It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well... Diazepinomicin is a natural product derived from a non-pathogenic micro-organism.
- Mechanism
- Curator reviewed
Diazepinomicin demonstrates broad in vitro cytotoxic activity across a diverse panel of tumour cell lines and in vivo efficacy in a number of xenograft tumour models. Preclinical data suggest that diazepinomicin is a targeted anti-cancer agent with dual activity: selective binding to the peripheral benzodiazepine receptor (PBR) and inhibition of the Ras-MAPK pathway.
- Formula / weight
- C28H34N2O4 · 462.59 g/mol (avg)
- Code names
- AMO-01 · BU-4664L · ECO-4601 · TLN-4601
Resolves to
SALVHVNECODMJP-GNUCVDFRSA-NSMILESCC(C)=CCC\C(C)=C\CC\C(C)=C\CN1C2=CC(O)=CC(O)=C2NC2=C(C=CC=C2O)C1=OWhat you can answer from here — as of July 16, 2025
Which drugs share a target with Diazepinomicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account